TERT promoter and TP53 mutations are the most frequently encountered molecular alterations in ATCs, followed by BRAF and RAS, whereas NTRK and RET fusions are detected in 2–3% of ATCs [61,66]. This evidence concerns the gene BRAF and Ehlers-Danlos syndrome, musculocontractural type.